Papillary Renal Cell Carcinoma: Outcomes for Patients Receiving First-line Immune-based Combinations or Tyrosine Kinase Inhibitors from the ARON-1 Study

Autor:	Massari, Francesco, Mollica, Veronica, Fiala, Ondrej, De Giorgi, Ugo, Kucharz, Jakub, Vitale, Maria Giuseppa, Molina-Cerrillo, Javier, Facchini, Gaetano, Seront, Emmanuel, Lenci, Edoardo, Bourlon, Maria T., Carrozza, Francesco, Pichler, Renate, Lolli, Cristian, Myint, Zin W., Kanesvaran, Ravindran, Torniai, Mariangela, Rescigno, Pasquale, Gomez de Liaño, Alfonso, Zakopoulou, Roubini, Buti, Sebastiano, Porta, Camillo, Grande, Enrique, Santoni, Matteo
Zdroj:	In European Urology Oncology October 2024 7(5):1123-1131
Databáze:	ScienceDirect
Externí odkaz:	Zobrazit plný text záznamu Full Text from ScienceDirect